# Treatment of Autoimmune Thrombocytopenia (AITP)

> **NCT00001630** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 29 (actual)

## Conditions studied

- Autoimmune Disease
- Autoimmune Hemolytic Anemia
- Thrombocytopenia

## Interventions

- **DEVICE:** Isolex 300i

## Key facts

- **NCT ID:** NCT00001630
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07-21
- **Primary completion:** —
- **Final completion:** 2009-06-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001630, "Treatment of Autoimmune Thrombocytopenia (AITP)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00001630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*